Social media

A new qualitative study in BMC Musculoskeletal Disorders confirms the content validity of the Oswestry Disability Index instrument for individuals with Degenerative Disc Disease. The research shows high alignment betwe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® explores the evolving NIT landscape, emerging regulat...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/Q1...

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/JE...

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...

New analyses show that well-implemented DHTs can: - Reduce trial timelines by 3–5 months - Decrease enrollment requirements by up to 16% - Lower protocol amendment risk - Deliver meaningful ROI in both Phase II and Phase...

New analyses show that well-implemented DHTs can: - Reduce trial timelines by 3–5 months - Decrease enrollment requirements by up to 16% - Lower protocol amendment risk - Deliver meaningful ROI in both Phase II and Phase...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...